BOND-VALE — CANON

inherits: hadleylab-canonic/SERVICES/DECK privacy: PUBLIC view: gov

Axiom

THE PR BRIEFING IS A GOVERNED ARTIFACT. EVERY CLAIM TRACES TO VITAE, PAPERS, OR CLINICALTRIALS.GOV. EVERY FIGURE VERIFIED. EVERY ANGLE SOURCED.

Constraints

MUST:     Every figure traces to VITAE, paper, ClinicalTrials.gov, or governed scope
MUST:     Every product URL resolves to a live surface
MUST:     Align with PMWC deck figures (no drift between decks)
MUST:     $38M = total PI across career (not single institution)
MUST:     67 publications = PubMed-verified journal articles (not Google Scholar total)
MUST:     20K interactions = MammoChat production (NCT06604078)
MUST:     6 patent families = filed 2026-02-25 (provisionals, 12-month conversion window)
MUST:     EU AI Act date = August 2, 2026 (enforcement, not passage)
MUST NOT: Hallucinate uncited claims
MUST NOT: Use "blockchain" in external messaging (JoAnn Yamani feedback: crypto confusion)
MUST NOT: Claim FDA clearance (not yet filed)
MUST NOT: Claim revenue or paying customers (foundation stage)

Sources

Source Role
VITAE Every credential, trial, grant, publication
PAPERS/the-255-billion-dollar-wound.md $255B market, 82% preventable, 212:1 ROI
PATENTS/PATENTS.md 6 families, 129 claims, zero blockers
TALKS/MAMMOCHAT Product spec, NCT06604078, 20K interactions
TALKS/CARIBCHAT 15 OECS nations, CAOH launch July 2026
TALKS/OMICSCHAT StarGEO heritage, Flatiron partnership
TALKS/RUNNER GoRunner spec, COIN economics
PMWC DECK Competitive landscape, pitch architecture
ACHIEVE DECK Killer lines, episode flow, marketing points
BLOGS 65 posts, 16 eras (narrative sourcing)
*BOND-VALE CANON DECK*